Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation.
Buprenorphine–naloxone
GBOT
Group psychotherapy
Group visit
Implementation science
Shared medical appointment
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
27 12 2019
27 12 2019
Historique:
received:
13
05
2019
accepted:
11
12
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
4
9
2020
Statut:
epublish
Résumé
Group-Based Opioid Treatment (GBOT) has recently emerged as a mechanism for treating patients with opioid use disorder (OUD) in the outpatient setting. However, the more practical "how to" components of successfully delivering GBOT has received little attention in the medical literature, potentially limiting its widespread implementation and utilization. Building on a previous case series, this paper delineates the key components to implementing GBOT by asking: (a) What are the core components to GBOT implementation, and how are they defined? (b) What are the malleable components to GBOT implementation, and what conceptual framework should providers use in determining how to apply these components for effective delivery in their unique clinical environment? To create a blueprint delineating GBOT implementation, we integrated findings from a previously conducted and separately published systematic review of existing GBOT studies, conducted additional literature review, reviewed best practice recommendations and policies related to GBOT and organizational frameworks for implementing health systems change. We triangulated this data with a qualitative thematic analysis from 5 individual interviews and 2 focus groups representing leaders from 5 different GBOT programs across our institution to identify the key components to GBOT implementation, distinguish "core" and "malleable" components, and provide a conceptual framework for considering various options for implementing the malleable components. We identified 6 core components to GBOT implementation that optimize clinical outcomes, comply with mandatory policies and regulations, ensure patient and staff safety, and promote sustainability in delivery. These included consistent group expectations, team-based approach to care, safe and confidential space, billing compliance, regular monitoring, and regular patient participation. We identified 14 malleable components and developed a novel conceptual framework that providers can apply when deciding how to employ each malleable component that considers empirical, theoretical and practical dimensions. While further research on the effectiveness of GBOT and its individual implementation components is needed, the blueprint outlined here provides an initial framework to help office-based opioid treatment sites implement a successful GBOT approach and hence potentially serve as future study sites to establish efficacy of the model. This blueprint can also be used to continuously monitor how components of GBOT influence treatment outcomes, providing an empirical framework for the ongoing process of refining implementation strategies.
Sections du résumé
BACKGROUND
Group-Based Opioid Treatment (GBOT) has recently emerged as a mechanism for treating patients with opioid use disorder (OUD) in the outpatient setting. However, the more practical "how to" components of successfully delivering GBOT has received little attention in the medical literature, potentially limiting its widespread implementation and utilization. Building on a previous case series, this paper delineates the key components to implementing GBOT by asking: (a) What are the core components to GBOT implementation, and how are they defined? (b) What are the malleable components to GBOT implementation, and what conceptual framework should providers use in determining how to apply these components for effective delivery in their unique clinical environment?
METHODS
To create a blueprint delineating GBOT implementation, we integrated findings from a previously conducted and separately published systematic review of existing GBOT studies, conducted additional literature review, reviewed best practice recommendations and policies related to GBOT and organizational frameworks for implementing health systems change. We triangulated this data with a qualitative thematic analysis from 5 individual interviews and 2 focus groups representing leaders from 5 different GBOT programs across our institution to identify the key components to GBOT implementation, distinguish "core" and "malleable" components, and provide a conceptual framework for considering various options for implementing the malleable components.
RESULTS
We identified 6 core components to GBOT implementation that optimize clinical outcomes, comply with mandatory policies and regulations, ensure patient and staff safety, and promote sustainability in delivery. These included consistent group expectations, team-based approach to care, safe and confidential space, billing compliance, regular monitoring, and regular patient participation. We identified 14 malleable components and developed a novel conceptual framework that providers can apply when deciding how to employ each malleable component that considers empirical, theoretical and practical dimensions.
CONCLUSION
While further research on the effectiveness of GBOT and its individual implementation components is needed, the blueprint outlined here provides an initial framework to help office-based opioid treatment sites implement a successful GBOT approach and hence potentially serve as future study sites to establish efficacy of the model. This blueprint can also be used to continuously monitor how components of GBOT influence treatment outcomes, providing an empirical framework for the ongoing process of refining implementation strategies.
Identifiants
pubmed: 31882001
doi: 10.1186/s13722-019-0176-y
pii: 10.1186/s13722-019-0176-y
pmc: PMC6935085
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Subventions
Organisme : NCCIH NIH HHS
ID : R21 AT010125
Pays : United States
Organisme : NCCIH NIH HHS
ID : R33 AT010125
Pays : United States
Références
J Stud Alcohol. 1997 Jan;58(1):7-29
pubmed: 8979210
Prev Sci. 2012 Feb;13(1):27-35
pubmed: 21826476
J Subst Abuse Treat. 2010 Oct;39(3):202-9
pubmed: 20598838
Addict Behav. 2010 May;35(5):537-40
pubmed: 20106601
Int J Offender Ther Comp Criminol. 2011 Oct;55(7):1135-53
pubmed: 20921264
J Consult Clin Psychol. 2014 Dec;82(6):964-72
pubmed: 25090043
Ann Intern Med. 2018 Nov 6;169(9):628-635
pubmed: 30357262
Drug Alcohol Depend. 2012 Dec 1;126(3):379-83
pubmed: 22704124
J Gen Intern Med. 2005 Nov;20(11):1038-41
pubmed: 16307630
Drug Alcohol Depend. 2000 Feb 1;58(1-2):55-66
pubmed: 10669055
Am J Addict. 2013 Nov-Dec;22(6):574-80
pubmed: 24131165
Drug Alcohol Depend. 2017 May 1;174:9-16
pubmed: 28282523
N Engl J Med. 2018 Jul 5;379(1):4-6
pubmed: 29972745
Occup Ther Int. 2008;15(4):205-20
pubmed: 18844242
Drug Alcohol Depend. 1995 Nov;40(1):17-25
pubmed: 8746920
MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82
pubmed: 26720857
J Gen Intern Med. 2006 Feb;21 Suppl 2:S58-64
pubmed: 16637962
Subst Abus. 2018 Jan 2;39(1):52-58
pubmed: 28723302
Addiction. 1998 Apr;93(4):475-86
pubmed: 9684386
Pain Physician. 2011 Mar-Apr;14(2):123-43
pubmed: 21412368
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Arch Gen Psychiatry. 2006 Feb;63(2):201-8
pubmed: 16461864
Subst Abus. 2019;40(2):132-135
pubmed: 30714880
Drug Alcohol Depend. 2007 Sep 6;90(1):39-47
pubmed: 17446014
J Adv Nurs. 2002 Apr;38(1):94-104
pubmed: 11895535
Cochrane Database Syst Rev. 2002;(4):CD002209
pubmed: 12519570
J Consult Clin Psychol. 2008 Dec;76(6):1068-75
pubmed: 19045974
Brain Res. 2009 Oct 13;1293:61-75
pubmed: 19332030
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75
pubmed: 25747920
Clin Pharmacol Ther. 1990 Apr;47(4):525-34
pubmed: 2328561
Int J Addict. 1989 May;24(5):425-34
pubmed: 2793290
Psychotherapy (Chic). 2011 Mar;48(1):43-9
pubmed: 21401273
Lancet. 1998 Sep 26;352(9133):1054-5
pubmed: 9759769
Exp Clin Psychopharmacol. 2002 Feb;10(1):54-63
pubmed: 11866252
Ann Fam Med. 2012 Sep-Oct;10(5):396-400
pubmed: 22966102
JAMA Psychiatry. 2014 May;71(5):547-56
pubmed: 24647726
Drug Alcohol Depend. 2012 Apr 1;122(1-2):86-92
pubmed: 21981991
Harv Rev Psychiatry. 1994 Jul-Aug;2(2):84-96
pubmed: 9384886
Am J Obstet Gynecol. 2017 Oct;217(4):459.e1-459.e6
pubmed: 28669739
Psychol Addict Behav. 2013 Sep;27(3):878-84
pubmed: 23025709
J Subst Abuse Treat. 2019 Dec;107:1-7
pubmed: 31757259
Pain Physician. 2006 Apr;9(2):123-9
pubmed: 16703972
Addiction. 2020 Jan;115(1):82-94
pubmed: 31430414
Addiction. 2001 May;96(5):683-90
pubmed: 11331027
Subst Abus. 2015;36(2):166-9
pubmed: 25738320
J Subst Abuse Treat. 2016 Jan;60:6-13
pubmed: 26233698
Drug Alcohol Depend. 2013 Oct 1;132(3):580-6
pubmed: 23688843
Addiction. 2017 May;112(5):830-837
pubmed: 27936293
J Consult Clin Psychol. 1992 Dec;60(6):927-34
pubmed: 1460154
Int J Group Psychother. 2000 Jul;50(3):297-314
pubmed: 10883547
Life Sci. 1994;54(17):1215-28
pubmed: 8164503
J Subst Abuse Treat. 1993 Sep-Oct;10(5):439-44
pubmed: 8246317
Drug Alcohol Depend. 1999 Apr 1;54(2):127-35
pubmed: 10217552
J Addict Med. 2014 Sep-Oct;8(5):299-308
pubmed: 25254667
Am J Ther. 2005 Sep-Oct;12(5):379-84
pubmed: 16148422
JAMA Intern Med. 2015 May;175(5):809-11
pubmed: 25774743
Subst Abus. 2020;41(2):174-180
pubmed: 31418638
Am J Psychiatry. 2017 Aug 1;174(8):738-747
pubmed: 27978771
N Engl J Med. 2003 Sep 4;349(10):949-58
pubmed: 12954743
Pain Med. 2012 Jul;13(7):886-96
pubmed: 22694154
Exp Clin Psychopharmacol. 2008 Apr;16(2):132-43
pubmed: 18489017
BMJ. 2008 Aug 07;337:a1035
pubmed: 18687726
Contemp Clin Trials. 2017 Mar;54:25-35
pubmed: 27979754
Drug Alcohol Rev. 2015 Nov;34(6):663-72
pubmed: 25919396
J Health Care Poor Underserved. 1999 May;10(2):216-29
pubmed: 10224827
J Consult Clin Psychol. 1998 Apr;66(2):290-303
pubmed: 9583332
Am J Psychiatry. 2005 Feb;162(2):340-9
pubmed: 15677600
Addiction. 2008 Jan;103(1):119-25
pubmed: 18028521
Drug Alcohol Depend. 2017 Sep 1;178:318-339
pubmed: 28688295
Addiction. 2014 Sep;109(9):1426-36
pubmed: 24750232
Br J Psychol. 2015 May;106(2):217-34
pubmed: 24905387
Drug Alcohol Depend. 2014 Nov 1;144:1-11
pubmed: 25179217
Pain Pract. 2010 Sep-Oct;10(5):428-50
pubmed: 20492579
Am J Drug Alcohol Abuse. 2007;33(1):5-11
pubmed: 17366241
Am J Drug Alcohol Abuse. 2011 Sep;37(5):453-9
pubmed: 21854290
J Psychiatr Res. 1964 Jun;2:61-72
pubmed: 14177091
Drug Alcohol Depend. 2015 Jul 1;152:62-7
pubmed: 25982007
J Addict Med. 2015 Sep-Oct;9(5):358-67
pubmed: 26406300
J Consult Clin Psychol. 2013 Feb;81(1):23-34
pubmed: 23106760
J Addict Dis. 2012;31(1):8-18
pubmed: 22356665
Arch Gen Psychiatry. 2001 Aug;58(8):755-61
pubmed: 11483141
JAMA Intern Med. 2014 Dec;174(12):1947-54
pubmed: 25330017
J Subst Abuse Treat. 2014 Sep;47(3):202-12
pubmed: 24953168
Lancet. 2003 Feb 22;361(9358):662-8
pubmed: 12606177
Arch Gen Psychiatry. 2005 Oct;62(10):1148-56
pubmed: 16203960
JAMA. 2013 Feb 20;309(7):657-9
pubmed: 23423407
Int J Group Psychother. 1999 Oct;49(4):429-64
pubmed: 10530045
Drug Alcohol Depend. 1986 Dec;18(4):341-8
pubmed: 3816530
Ann Fam Med. 2014 Mar-Apr;12(2):128-33
pubmed: 24615308
Addiction. 2005 Mar;100(3):304-16
pubmed: 15733244
Subst Abus. 2018;39(2):211-217
pubmed: 29522381
Implement Sci. 2008 May 29;3:29
pubmed: 18510749
J Subst Abuse Treat. 2018 Jan;84:78-87
pubmed: 29195596
Subst Abuse Treat Prev Policy. 2011 Jul 19;6:17
pubmed: 21771314
Psychol Addict Behav. 2008 Dec;22(4):533-43
pubmed: 19071978
Fam Med. 2006 May;38(5):336-40
pubmed: 16673195
J Subst Abuse Treat. 2008 Dec;35(4):387-95
pubmed: 18424048
J Subst Abuse Treat. 2010 Jul;39(1):41-50
pubmed: 20434868
J Gen Intern Med. 2019 Feb;34(2):293-302
pubmed: 30511291
J Am Board Fam Med. 2014 Mar-Apr;27(2):229-38
pubmed: 24610185
Am J Addict. 1999 Fall;8(4):279-92
pubmed: 10598211
Neuropsychopharmacology. 2000 Sep;23(3):326-34
pubmed: 10942856
Addict Behav. 1996 Nov-Dec;21(6):779-88
pubmed: 8904943
Drug Alcohol Depend. 2010 Mar 1;107(2-3):253-6
pubmed: 19948382
J Subst Abuse Treat. 2017 Jul;78:1-7
pubmed: 28554597
Addict Sci Clin Pract. 2008 Jun;4(2):39-47
pubmed: 18497717
Psychiatry Res Neuroimaging. 2016 Apr 30;250:12-4
pubmed: 27107155
Arch Gen Psychiatry. 2011 Dec;68(12):1238-46
pubmed: 22065255
Behav Res Ther. 2008 Oct;46(10):1170-5
pubmed: 18675399
BMC Med Res Methodol. 2011 Jun 27;11:100
pubmed: 21707982
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
J Am Acad Child Adolesc Psychiatry. 2011 Dec;50(12):1265-74
pubmed: 22115147
J Subst Abuse Treat. 1996 Jan-Feb;13(1):51-9
pubmed: 8699543
Addiction. 2018 Dec;113(12):2250-2258
pubmed: 30238568
Int J Addict. 1978 Jul;13(5):737-46
pubmed: 721332
Am J Psychiatry. 2007 Jan;164(1):100-7
pubmed: 17202550
Drug Alcohol Depend. 2002 Jun 1;67(1):13-26
pubmed: 12062776
Drug Alcohol Depend. 2015 Oct 1;155:1-7
pubmed: 26298552
Biol Psychiatry. 2007 Jan 1;61(1):101-10
pubmed: 16950210
Am J Obstet Gynecol. 2017 Jan;216(1):64.e1-64.e7
pubmed: 27687214
J Psychoactive Drugs. 2013 Jan-Mar;45(1):17-27
pubmed: 23662328